Default company panoramic image


Solutions for a Lifetime for cardiovascular patients

  • Stage Product In Development
  • Industry Medical Devices and Equipment
  • Location 8001 Zurich, ZH, Switzerland
  • Currency USD
  • Founded November 2006
  • Employees 16
  • Website

Company Summary

Xeltis is a privately held medical device company dedicated to transforming standards of care in heart valve replacement and vascular surgery. The company’s proprietary COR (Cardiac Organ Regeneration) technology combines novel biodegradable biomaterials with sophisticated material processing methods to deliver an implant prosthesis that allows patients to regrow organs in their own bodies, using their own cells.


  • Default avatar
    Laurent Grandidier

    Mr. Grandidier joined Xeltis from medical device company Endosense where he was Vice-President in charge of global commercialization, portfolio management and strategic initiatives. He held leadership positions at brand name global medical device companies: Teleflex Medical where he led a 100mUSD subsidiary, Boston Scientific and Guidant where he had international marketing responsibilities. He holds an MSC from INSA-Lyon and an MBA from INSEAD.

  • Default avatar
    Oleg Svanizde

    Dr. Oleg Svanidze, MD, PhD, is a seasoned medical device industry professional. Oleg joined Xeltis from Allergan where he was Senior Medical Director. Prior to Allergan, Oleg held executive positions in several cardiovascular startups including Arbor Surgical Technologies, 3F Therapeutics (now Medtronic), Computer Motion (now Intuitive Surgical) and Heartport (now Edwards Lifesciences). Oleg is a trained cardiac surgeon and holds multiple patents

  • Default avatar
    Andreas Emmendoerffer
    VP Operations

    Dr. Andreas Emmendörffer is Vice-President of Operations. Before joining Xeltis he successfully founded and led two biotech companies after having headed the German Operations of Modex. He started his career in applied research at the Fraunhofer Society, Hannover, where he headed the department of Immunotoxicology. Dr. Emmendörffer holds a MD and Professorship in “Experimental and Clinical Immunology” degree of Medical School Hannover.

  • Default avatar
    Mirjam Rubbens
    Director of R&D

    Dr. ir. Mirjam Rubbens (PhD, MBI) is Director of R&D at Xeltis. She was a co-founder of life science company QTIS/e that focused on the development of tissue-engineered heart valves and blood vessels. Mrs. Rubbens holds a MSc in biomedical engineering (cum laude), a PhD in living cardiovascular tissues and an entrepreneurial MBA at TiasNimbas Business School, Tilburg University, The Netherlands.

  • Default avatar
    Marijn Cox
    Director of R&D and GM Eindhoven

    Dr. Martijn Cox is the General Manager of Xeltis Einhoven office and Director of R&D. He has nearly 10 years of experience in the field of cardiovascular regeneration. He was the co-founder QTIS/e as a spin-off of the Eindhoven University of Technology, which joined forces with Xeltis in 2012. Martijn holds a PhD in cardiovascular tissue engineering and an MBA in Business Innovation from the TiasNimbas business school.


  • Default avatar
    Ante Treuhand

Previous Investors

  • Default avatar
    Private investors
    Default avatar
    Zurich Kantonal Bank